"Oncogene Protein v-akt" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A viral oncoprotein originally isolated from a murine T CELL LYMPHOMA infected with the acutely transforming retrovirus AKT8. v-akt protein is the viral homologue of PROTO-ONCOGENE PROTEINS C-AKT.
| Descriptor ID |
D051058
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.586 D12.776.624.664.520.750.788
|
| Concept/Terms |
Oncogene Protein v-akt- Oncogene Protein v-akt
- Oncogene Protein v akt
- v-akt, Oncogene Protein
- v-akt Protein
- v-akt Kinase Transforming Protein
- v akt Kinase Transforming Protein
- akt-Oncogene Protein
- akt Oncogene Protein
- Oncogene Protein akt
- akt, Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Protein v-akt".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Protein v-akt".
This graph shows the total number of publications written about "Oncogene Protein v-akt" by people in this website by year, and whether "Oncogene Protein v-akt" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2005 | 0 | 5 | 5 |
| 2006 | 2 | 6 | 8 |
| 2007 | 2 | 2 | 4 |
| 2008 | 0 | 2 | 2 |
| 2009 | 3 | 4 | 7 |
| 2010 | 3 | 4 | 7 |
| 2011 | 3 | 5 | 8 |
| 2012 | 1 | 2 | 3 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 6 | 6 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncogene Protein v-akt" by people in Profiles.
-
Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression. Cancer Res. 2020 09 15; 80(18):3810-3819.
-
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. Clin Cancer Res. 2019 02 15; 25(4):1272-1279.
-
AhR ligand aminoflavone suppresses a6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells. J Cell Physiol. 2018 01; 234(1):108-121.
-
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018 08 15; 24(16):3967-3980.
-
Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018 05; 15(5):273-291.
-
RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression. Cancer Res. 2017 08 15; 77(16):4247-4257.
-
A genetic interaction analysis identifies cancer drivers that modify EGFR dependency. Genes Dev. 2017 01 15; 31(2):184-196.
-
MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694.
-
MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694.
-
MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694.